Product logins

Find logins to all Clarivate products below.


Afatinib Dimaleate

GILOTRIF®

About GILOTRIF®

  • Marketed by Boehringer Ingelheim Pharmaceuticals, Inc
  • Orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family
  • First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations

Review and approval status

July 12, 2013

First U.S. approval

September 25, 2013

First E.U. approval

Constraint date forecast:

  • 2026: Patent expiry: United States
  • 2026: SPC expiry: European Union
  • 2026: Patent expiry: Japan

API availability

*Source: Cortellis Generics Intelligence